Repros Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: The Woodlands TX United States (2006)
Status: Acquired by Allergan PLC (2015) (2017) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2006
NCT01069094
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Repros Therapeutics Inc. | Zonagen

Active Ingredients

Drugs in Phase 3 Trials (3)

enclomiphene (23 trials)

progenta (34 trials)

testosterone (delatestryl) (7 trials)

Drugs in Phase 2 Trials (4)

clomifene (clomid) (1 trial)

leuprolide (lupron) (2 trials)

telepristone (1 trial)

trans-clomiphene (1 trial)

Drugs in Phase 1 Trials (1)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amenorrhea (Phase 2)

Breast Neoplasms (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Endometriosis (Phase 2)

Hypogonadism (Phase 3)

Leiomyoma (Phase 3)

Myofibroma (Phase 3)

Neoplasm Metastasis (Phase 3)

Overweight (Phase 3)

Recurrence (Phase 3)

Renal Insufficiency (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 59
  • # of Trial APIs: 8